Article
Drug Combo Improves Activity in Heart Failure Patients
Author(s):
Treatment with sacubitril/valsartan (Entresto) improved several types of physical and social activities in heart failure patients with reduced ejection fraction compared with enalapril.
Results published in JAMA Cardiology from a PARADIGM-HF post-hoc analysis demonstrates that treatment with sacubitril/valsartan (Entresto) significantly improved 7 of 10 types of physical and social activities at 8 months in heart failure patients with reduced ejection fraction (HFrEF) versus patients taking enalapril.
The improvement in combined physical and social activity of patients with Entresto versus enalapril was equivalent to a difference of 9 years of aging. The most significant developments included the ability to carry out household chores and the ability to conduct intimate/sexual relationships.
“What we’ve done now is we’ve looked at the way people feel, the symptoms that they have, the limitations that they have, both in physical and social domains,” Scott Solomon, MD, Brigham and Women’s Hospital, told MD Magazine. “What we found is that in virtually all of these domains, all of these questions, patients reported improvement in their limitations if they were randomized to sacubitril compared to those who were randomized to enalapril.”
Click to continue reading on MD Magazine.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
